Bank of America’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-202,414
| Closed | -$8.02M | – | 8534 |
|
|
2024
Q1 | $8.02M | Buy |
202,414
+110,648
| +121% | +$3.26M | ﹤0.01% | 3194 |
|
|
2023
Q4 | $1.75M | Buy |
91,766
+70,466
| +331% | +$979K | ﹤0.01% | 4541 |
|
|
2023
Q3 | $244K | Buy |
21,300
+3,385
| +19% | +$41.7K | ﹤0.01% | 5782 |
|
|
2023
Q2 | $184K | Sell |
17,915
-5,585
| -24% | -$50.4K | ﹤0.01% | 5891 |
|
|
2023
Q1 | $181K | Sell |
23,500
-166
| -0.7% | -$1.32K | ﹤0.01% | 5972 |
|
|
2022
Q4 | $174K | Buy |
23,666
+17,075
| +259% | +$109K | ﹤0.01% | 5987 |
|
|
2022
Q3 | $47K | Sell |
6,591
-3,284
| -33% | -$27.1K | ﹤0.01% | 6708 |
|
|
2022
Q2 | $85K | Sell |
9,875
-5,567
| -36% | -$48K | ﹤0.01% | 6559 |
|
|
2022
Q1 | $138K | Buy |
15,442
+10,498
| +212% | +$90.8K | ﹤0.01% | 6689 |
|
|
2021
Q4 | $69K | Buy |
4,944
+1,573
| +47% | +$19.5K | ﹤0.01% | 7064 |
|
|
2021
Q3 | $36K | Buy |
3,371
+1,145
| +51% | +$10.6K | ﹤0.01% | 7194 |
|
|
2021
Q2 | $20K | Buy |
2,226
+1,048
| +89% | +$11.4K | ﹤0.01% | 7134 |
|
|
2021
Q1 | $12K | Buy |
+1,178
| New | +$14.7K | ﹤0.01% | 6983 |
|
|
2020
Q3 | – | Sell |
-29
| Closed | – | – | 7254 |
|
|
2020
Q2 | $0 | Buy |
+29
| New | +$125 | ﹤0.01% | 7197 |
|
|
2019
Q4 | – | Sell |
-366
| Closed | -$1K | – | 7499 |
|
|
2019
Q3 | $1K | Buy |
366
+352
| +2,514% | +$1.51K | ﹤0.01% | 7160 |
|
|
2019
Q2 | $0 | Buy |
+14
| New | +$81 | ﹤0.01% | 7473 |
|
|
2019
Q1 | – | Sell |
-1,105
| Closed | -$4K | – | 7480 |
|
|
2018
Q4 | $4K | Buy |
+1,105
| New | +$5.45K | ﹤0.01% | 6806 |
|
|
2018
Q3 | – | Sell |
-2
| Closed | – | – | 7522 |
|
|
2018
Q2 | $0 | Sell |
2
-638
| -100% | -$5.26K | ﹤0.01% | 7386 |
|
|
2018
Q1 | $5K | Buy |
+640
| New | +$6.32K | ﹤0.01% | 6775 |
|
|
2017
Q4 | – | Sell |
-4
| Closed | – | – | 7309 |
|
|
2017
Q3 | $0 | Buy |
+4
| New | +$37 | ﹤0.01% | 7334 |
|
|
2016
Q4 | – | Sell |
-453
| Closed | -$15K | – | 7386 |
|
|
2016
Q3 | $15K | Sell |
453
-492
| -52% | -$12K | ﹤0.01% | 6242 |
|
|
2016
Q2 | $17K | Buy |
945
+519
| +122% | +$9.21K | ﹤0.01% | 6322 |
|
|
2016
Q1 | $7K | Buy |
426
+145
| +52% | +$2.9K | ﹤0.01% | 6494 |
|
|
2015
Q4 | $9K | Buy |
+281
| New | +$9.59K | ﹤0.01% | 6729 |
|
Bank of America's ALPN Position: Q2 2024 in Review
Bank of America sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 202,414 shares — an estimated $8.02M sold.
Bank of America first reported a position in ALPN in Q4 2015 and held it in 24 quarters. The position peaked at $8.02M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Bank of America reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Bank of America sold 202,414 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $8.02M.
- Bank of America first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 24 quarters.
- Bank of America's Alpine Immune Sciences Inc position peaked at $8.02M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.